4basebio PLC (ETR:88Q)

Market Cap	85.27M -46.1%
Revenue (ttm)	1.94M +81.5%
Net Income	-19.38M
EPS	-1.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	284
Open	5.10
Previous Close	5.10
Day's Range	5.10 - 5.25
52-Week Range	4.64 - 10.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 21, 2026

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modificatio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 140
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 88Q

Financial Performance

In 2025, 4basebio's revenue was 1.69 million, an increase of 81.46% compared to the previous year's 933,000. Losses were -16.91 million, 37.1% more than in 2024.

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 24, 2026

Data Sources Report a data error